A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors MedImmune
- 31 Aug 2018 Biomarkers information updated
- 08 May 2009 Other source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 08 Apr 2009 Actual patient number (14) added as reported by ClinicalTrials.gov.